文献速递乳腺癌放疗

pN0(i+)与pN1mi乳腺癌:现代时代的治疗与结局并与pN0和pN1a比较

pN0(i+) and pN1mi Breast Cancer: Treatment and Outcomes in Comparison With pN0 and pN1a in the Modern Era.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-04-03

本研究纳入2006至2011年转诊的10271例新诊断pT1-T2、pN0、pN0(i+)、pN1mi或pN1a、M0乳腺癌患者,比较各组10年局部区域无复发生存(LRRFS),并按局部区域治疗分析LRRFS。中位随访9.3年,pN0(i+)和pN1mi患者接受局部区域放疗后10年局部区域复发风险≤10%;LRRT与pN1mi的LRRFS改善呈趋势相关,而与pN0(i+)无显著相关。

要点

  • pN0(i+)和pN1mi患者接受LRRT后10年局部区域复发风险≤10%。
  • LRRT与pN1mi的LRRFS改善呈趋势相关(HR 0.2;95%CI 0.03-1.1;P=.07)。
  • 全身治疗与pN0(i+)和pN1mi患者的LRRFS改善相关。

核心结论

  • 在哨兵淋巴结分期和现代全身治疗时代,接受LRRT的pN0(i+)和pN1mi患者经保乳手术或乳房切除加放疗后10年局部区域复发风险≤10%。
  • LRRT与pN1mi的LRRFS改善呈趋势相关,但与pN0(i+)无显著相关。

研究设计与样本

  • 研究纳入2006年至2011年间转诊的10271例新诊断pT1-T2、pN0、pN0(i+)、pN1mi或pN1a、M0乳腺癌患者。
  • 结局为10年Kaplan-Meier LRRFS、无复发生存(RFS)、无远处复发生存和乳腺癌特异性生存。
  • 在pN0(i+)和pN1mi队列中进行LRRFS和RFS的多变量分析。

主要发现

  • 中位随访9.3年。
  • pN0(n=7492)、pN0(i+)(n=305)、pN1mi(n=619)和pN1a(n=1855)患者中,LRRT使用率分别为1.1%、24.3%、45.7%和71.1%。
  • 10年LRRFS分别为96%、92%、97%和96%(P<.001),10年无远处复发生存分别为94%、91%、90%和84%(P<.001),10年乳腺癌特异性生存分别为95%、90%、93%和87%(P<.001)。
  • pN0(i+)患者中,单纯保乳手术、保乳加乳房放疗和LRRT的10年LRRFS分别为81%、93%和91%(P=.16);pN1mi患者分别为94%、96%和100%(P=.02)。
  • 乳房切除患者中,pN0(i+)单纯手术与LRRT的10年LRRFS分别为93%和100%(P=.12);pN1mi分别为95%和99%(P=.09)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Locoregional recurrence risk and the role of locoregional radiation therapy (LRRT) in pN0(i+) and pN1mi breast cancer are unclear. This study compares locoregional relapse-free survival (LRRFS) in patients with pN0(i+) and pN1mi relative to pN0 and pN1a disease and evaluates LRRFS according to locoregional treatment. METHODS AND MATERIALS: We studied 10,271 patients referred between 2006 and 2011 with newly diagnosed pT1-T2, pN0, pN0(i+), pN1mi, or pN1a, M0 breast cancer. Outcomes were 10-year Kaplan-Meier LRRFS, relapse-free survival (RFS), distant relapse-free survival, and breast cancer-specific survival. Multivariable analysis of LRRFS and RFS was performed in pN0(i+) and pN1mi cohorts. RESULTS: Median follow-up was 9.3 years. In patients with pN0 (n = 7492), pN0(i+) (n = 305), pN1mi (n = 619), and pN1a (n = 1855) disease, LRRT was used in 1.1%, 24.3%, 45.7%, and 71.1%, respectively. Ten-year outcomes were LRRFS 96%, 92%, 97%, and 96% (P < .001), distant RFS 94%, 91%, 90%, and 84% (P < .001), and breast cancer-specific survival 95%, 90%, 93%, and 87% (P < .001), respectively. Ten-year LRRFS for patients treated with breast-conserving surgery alone, with breast RT, and with LRRT were 81%, 93%, and 91% for patients with pN0(i+) (P = .16) and 94%, 96%, and 100% for patients with pN1mi (P = .02), respectively. Among patients treated with mastectomy, 10-year LRRFS with surgery alone and with LRRT were 93% and 100% for patients with pN0(i+) (P = .12) and 95% and 99% for patients with pN1mi (P = .09). On multivariable analysis of patients with pN0(i+) and pN1mi, systemic therapy was associated with improved LRRFS in patients with pN0(i+) (hazard ratio [HR], 0.2; [0.06-0.6]; P = .005) and patients with pN1mi (HR, 0.1; [0.03-0.5]; P = .006). In patients with pN1mi, LRRT was associated with a trend toward increased LRRFS (HR, 0.2; [0.03-1.1]; P = .07). LRRT was not significantly associated with improved RFS in pN0(i+) or pN1mi disease. CONCLUSIONS: In the era of sentinel node staging and modern systemic therapy, patients with pN0(i+) and PN1mi treated with LRRT experienced 10-year LRR risks ≤10% after breast-conserving surgery or mastectomy and RT. LRRT was associated with a trend toward increased LRRFS in pN1mi but not pN0(i+) disease.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Dosani M, Hamilton SN, Gondara L, et al. pN0(i+) and pN1mi Breast Cancer: Treatment and Outcomes in Comparison With pN0 and pN1a in the Modern Era. Int J Radiat Oncol Biol Phys. 2022. PMID: 35385784. doi:10.1016/j.ijrobp.2022.03.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。